Clinical trials for second-line DLBCL used a 12-month relapse cutoff for eligibility, but this shouldn't be interpreted rigidly in practice. A patient relapsing at 13 months is biologically similar to one at 11 months and should still be strongly considered for CAR T-cell therapy over salvage chemotherapy and transplant.
Clinicians should not be deterred from using CD19 CAR T-cell therapy in patients who have previously received other CD19-targeting agents like tafasitamab. Preclinical and retrospective clinical data suggest prior exposure does not impair CAR T efficacy, and therefore re-testing for CD19 expression is unnecessary.
Data from both DLBCL and follicular lymphoma studies show that recent bendamustine exposure negatively impacts T-cell quality, leading to poorer CAR T-cell therapy outcomes. This effect is most pronounced if the drug was given within a year of T-cell collection, making it a critical factor in long-term treatment sequencing.
The 'brain to vein time'—from identifying a relapse to CAR T infusion—is critical. Early referral allows the specialty center to manage complex logistics like insurance authorization, organ function optimization, and patient travel, which can be significant barriers to care. Delays can mean a patient's condition deteriorates past the point of eligibility.
When choosing a bispecific antibody for follicular lymphoma, a major practical difference is the treatment duration. Mosunetuzumab is a time-limited therapy stopped after achieving a complete response, while Epcoritamab is given indefinitely until progression. This distinction heavily influences selection, especially for elderly patients.
Provocative data from a German study showed an 81% complete response rate in untreated, elderly DLBCL patients using a chemotherapy-free regimen of polatuzumab (an ADC), glofitamab (a bispecific), and rituximab. This challenges the decades-long R-CHOP chemotherapy backbone and points to a future of targeted frontline therapies.
Unlike autologous transplant, CAR T-cell therapy does not have strict age or organ function cutoffs. Patients over 75, or with conditions like an ejection fraction of 40%, can be eligible. The key pre-treatment goal is disease stability, not a deep response, making it accessible to a wider, less fit patient population.
While Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS) are dramatic acute side effects, they are rarely fatal. The leading cause of non-relapse mortality for patients receiving CAR T-cells or bispecifics is infection resulting from prolonged cytopenias. This underscores the need for vigilant monitoring and prophylaxis.
For mantle cell lymphoma patients on a BTK inhibitor who are progressing, the drug should be continued until immediately before leukapheresis for CAR T-cell therapy. Abruptly stopping the BTKi can lead to an explosive disease flare, potentially making the patient too unstable to proceed with T-cell collection.
The Hematotox score, a simple calculation using routine labs (CBC, CRP, ferritin), is a powerful predictor of prolonged cytopenias and subsequent high-grade infections after CAR T-cell therapy. This allows clinicians to risk-stratify patients and tailor supportive care, like prophylactic antibiotics, for those at highest risk.
While prophylactic tocilizumab is used to mitigate CRS with bispecific antibodies in multiple myeloma, this practice should not be applied to lymphoma patients. Rates of high-grade CRS with CD20-bispecifics in lymphoma are low single digits, making routine prophylaxis unnecessary and exposing patients to a drug they likely don't need.
Moving CAR T-cell therapy from the third-line to the second-line setting for high-risk DLBCL doesn't just improve survival curves, it meaningfully increases the cure fraction from approximately 40% to 50-55%. This quantifiable benefit provides a strong rationale for using CAR T therapy earlier in the disease course.